![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Integrated Analysis of Emergent Drug Resistance
from the HIV-1 Phase 3 QUAD Studies through Week 48
|
|
|
Reported by Jules Levin
International Workshop on HIV &
Hepatitis Virus Drug Resistance and Curative Strategies
June 5-9, 2012, Sitges, Spain
K White, R Kulkarni, J Szwarcberg, E Quirk, AK Cheng, and MD Miller
Gilead Sciences, Inc., California, USA
![resistance1.gif](../images/061812/061812-2/resistance1.gif)
![resistance2.gif](../images/061812/061812-2/resistance2.gif)
![resistance3.gif](../images/061812/061812-2/resistance3.gif)
![resistance4.gif](../images/061812/061812-2/resistance4.gif)
![resistance5.gif](../images/061812/061812-2/resistance5.gif)
![resistance6.gif](../images/061812/061812-2/resistance6.gif)
![resistance7.gif](../images/061812/061812-2/resistance7.gif)
![resistance8.gif](../images/061812/061812-2/resistance8.gif)
![resistance9.gif](../images/061812/061812-2/resistance9.gif)
![resistance10.gif](../images/061812/061812-2/resistance10.gif)
![resistance11.gif](../images/061812/061812-2/resistance11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|